Core Insights - Innovent Biologics, Inc. will present multiple research results at the 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, focusing on their monoclonal antibodies and bispecific antibodies for various skin diseases [1] Group 1: Research Presentations - The company will showcase post hoc analyses of Phase 2 and Phase 3 clinical studies of IBI112 (picankibart) and preclinical studies of IBI3013 and IAR129 through ePosters [1] - Specific presentations include the efficacy and safety of picankibart in patients with psoriasis and its effects on genital and nail psoriasis, as well as comparisons between biologic-experienced and biologic-naive patients [1] Group 2: Product Development and Pipeline - Picankibart, an anti-IL-23p19 monoclonal antibody, is expected to receive marketing approval by the end of 2025, offering rapid onset of action and long-interval quarterly dosing [1] - Innovent has a well-established pipeline with 16 products launched, 2 new drug applications under review, and 4 assets in Phase III trials, indicating a robust development strategy [3] Group 3: Company Vision and Commitment - The company aims to address unmet needs in skin diseases through innovative therapies and is committed to advancing global innovation in biopharmaceuticals [1] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [3]